Search research articles
Contact Us
Filters
Showing results (1-10 of 60) with videos related to
Page
of 6
Sort By:
Vaccines
|
May 27, 2023
The Economic Value of Rotavirus Vaccination When Optimally Implemented in a High-Income Country
Baudouin Standaert
Vaccines
|
November 25, 2023
Comment on Postma et al. Predicted Public Health and Economic Impact of Respiratory Syncytial Virus Vaccination with Variable Duration of Protection for Adults ≥60 Years in Belgium. <i>Vaccines</i> 2023, <i>11</i>, 990
Baudouin Standaert
Journal of Market Access & Health Policy
|
May 23, 2018
Towards a more comprehensive approach for a total economic assessment of vaccines?: 1. The building blocks for a health economic assessment of vaccination
Baudouin Standaert, Rino Rappuoli
Viruses
|
February 26, 2022
Defining the Recipe for an Optimal Rotavirus Vaccine Introduction in a High-Income Country in Europe
Baudouin Standaert, Bernd Benninghoff
Journal of Medical Economics
|
May 28, 2010
Modelling the economic value of cross- and sustained-protection in vaccines against cervical cancer
Nadia Demarteau, Baudouin Standaert
Journal of Market Access & Health Policy
|
May 23, 2018
2. How is the economic assessment of vaccines performed today?
Baudouin Standaert, Rino Rappuoli
Journal of Market Access & Health Policy
|
May 23, 2018
3. How comprehensive can we be in the economic assessment of vaccines?
Baudouin Standaert, Rino Rappuoli
Pharmacoeconomics
|
January 31, 2012
Population- versus cohort-based modelling approaches
Olivier Ethgen, Baudouin Standaert
Journal of Market Access & Health Policy
|
November 8, 2023
Discounting health gain: a different view
Baudouin Standaert, Olivier Ethgen
Vaccines
|
June 25, 2026
Proposed Conceptual and Experience-Based Framework for Reaching an Optimal Vaccine Launch Strategy
Baudouin Standaert, Marc Raes
Page
of 6
Search research articles
Search
Showing results (1-10 of 60) with videos related to
Sort By:
Page
of 6
Vaccines
|
May 27, 2023
The Economic Value of Rotavirus Vaccination When Optimally Implemented in a High-Income Country
Baudouin Standaert
Vaccines
|
November 25, 2023
Comment on Postma et al. Predicted Public Health and Economic Impact of Respiratory Syncytial Virus Vaccination with Variable Duration of Protection for Adults ≥60 Years in Belgium. <i>Vaccines</i> 2023, <i>11</i>, 990
Baudouin Standaert
Journal of Market Access & Health Policy
|
May 23, 2018
Towards a more comprehensive approach for a total economic assessment of vaccines?: 1. The building blocks for a health economic assessment of vaccination
Baudouin Standaert, Rino Rappuoli
Viruses
|
February 26, 2022
Defining the Recipe for an Optimal Rotavirus Vaccine Introduction in a High-Income Country in Europe
Baudouin Standaert, Bernd Benninghoff
Journal of Medical Economics
|
May 28, 2010
Modelling the economic value of cross- and sustained-protection in vaccines against cervical cancer
Nadia Demarteau, Baudouin Standaert
Journal of Market Access & Health Policy
|
May 23, 2018
2. How is the economic assessment of vaccines performed today?
Baudouin Standaert, Rino Rappuoli
Journal of Market Access & Health Policy
|
May 23, 2018
3. How comprehensive can we be in the economic assessment of vaccines?
Baudouin Standaert, Rino Rappuoli
Pharmacoeconomics
|
January 31, 2012
Population- versus cohort-based modelling approaches
Olivier Ethgen, Baudouin Standaert
Journal of Market Access & Health Policy
|
November 8, 2023
Discounting health gain: a different view
Baudouin Standaert, Olivier Ethgen
Vaccines
|
June 25, 2026
Proposed Conceptual and Experience-Based Framework for Reaching an Optimal Vaccine Launch Strategy
Baudouin Standaert, Marc Raes
Page
of 6